Skip to main content
. 2019 Dec 6;3(23):4021–4033. doi: 10.1182/bloodadvances.2019000617

Figure 2.

Figure 2.

Effects of different concentrations of irreversible BTKi’s on FcγRIIA-mediated platelet aggregation in blood stimulated by anti-CD9 antibody. Blood samples were preincubated for 60 minutes with solvent (DMSO, 0.1%) or BTKi’s (ibrutinib, acalabrutinib, tirabrutinib, zanubrutinib, and evobrutinib) before stimulation with anti-CD9 antibody (1 µg/mL) for 10 minutes. Values are mean ± SD (n = 5). *P < .05; **P < .01; ***P < .001.